Cite
HARVARD Citation
Grünewald, S. et al. (2019). Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models. International journal of cancer. 145 (5), pp. 1346-1357. [Online].